MEDS (DataMEDS AI) Earnings Yield (Joel Greenblatt) %: -208.33% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is DataMEDS AI Earnings Yield (Joel Greenblatt) %?

DataMEDS AI MEDS +2.23% Earnings Yield (Joel Greenblatt) % is -208.33% as of Jun. 2026. The stock has 7 warning signs investors should review. Among 125 Medical Distribution companies, DataMEDS AI ranks worse than 99.2% on this metric.

DataMEDS AI's Enterprise Value for the quarter that ended in Jun. 2026 was $39.12 Mil. DataMEDS AI's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-82.34 Mil. DataMEDS AI's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -208.33%.

The historical rank and industry rank for DataMEDS AI's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

MEDS' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -280.46   Med: -119.17   Max: -2.14
Current: -250

During the past 4 years, the highest Earnings Yield (Joel Greenblatt) of DataMEDS AI was -2.14%. The lowest was -280.46%. And the median was -119.17%.

MEDS's Earnings Yield (Joel Greenblatt) % is ranked worse than
99.2% of 125 companies
in the Medical Distribution industry
Industry Median: 5.93 vs MEDS: -250.00

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. DataMEDS AI's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


DataMEDS AI  (NAS:MEDS) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


DataMEDS AI Earnings Yield (Joel Greenblatt) % Related Terms


DataMEDS AI Earnings Yield (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for DataMEDS AI's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DataMEDS AI Earnings Yield (Joel Greenblatt) % Chart

DataMEDS AI Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Earnings Yield (Joel Greenblatt) %
0.00 0.00 0.00 -149.25

DataMEDS AI Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.26 -72.46 -149.25 -175.44 -208.33

MEDS vs SNYR, MCK, COR: Earnings Yield (Joel Greenblatt) % Comparison

For the Medical Distribution subindustry, DataMEDS AI's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DataMEDS AI Earnings Yield (Joel Greenblatt) % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, DataMEDS AI's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where DataMEDS AI's Earnings Yield (Joel Greenblatt) % falls into.



DataMEDS AI Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

DataMEDS AIs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-96.695/65.19435
=-148.32 %

DataMEDS AI's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.34 Mil.


What does a Earnings Yield (Joel Greenblatt) % of -208.33% mean?
DataMEDS AI (MEDS) has a Earnings Yield (Joel Greenblatt) % of -208.33% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on DataMEDS AI and its competitors. According to the industry distribution chart, DataMEDS AI ranks #124 out of 125 companies in the Medical Distribution industry, placing it in the top 99.2%.
Is DataMEDS AI's Earnings Yield (Joel Greenblatt) % too high?
DataMEDS AI's current Earnings Yield (Joel Greenblatt) % is -208.33%. Based on the distribution chart, DataMEDS AI ranks #124 out of 125 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers.
How does DataMEDS AI's Earnings Yield (Joel Greenblatt) % compare to SNYR and MCK?
According to the Medical Distribution industry distribution chart, DataMEDS AI ranks #124 out of 125 companies for Earnings Yield (Joel Greenblatt) %. This places DataMEDS AI in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 5.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Distribution company?
The median Earnings Yield (Joel Greenblatt) % among Medical Distribution companies is 5.93, based on 125 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on DataMEDS AI and its competitors. For the Medical Distribution industry, the median Earnings Yield (Joel Greenblatt) % is 5.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DataMEDS AI's current Earnings Yield (Joel Greenblatt) % is -208.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DataMEDS AI stock overvalued right now?
DataMEDS AI (MEDS) has a current Earnings Yield (Joel Greenblatt) % of -208.33%. The current Earnings Yield (Joel Greenblatt) % is -208.33%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For DataMEDS AI (MEDS), the current Earnings Yield (Joel Greenblatt) % is -208.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DataMEDS AI Business Description

Address 3000 Bayport Drive, Suite 950, Tampa, FL, USA, 33607
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.